Øystein Rekdal

Director Ejecutivo en LYTIX BIOPHARMA ASA .

Fortuna: 156 401 $ al 31/08/2026

Health Technology

Consumer Services

El acceso a esta página está reservado para miembros. Para continuar, inicia sesión o crea una cuenta.

Latest insider transactions

An executive increases exposure to an industrial stock

Sector rotation: insiders are more active on clean energy names

New regulatory filing published for executive transactions

Executive Management

Board of Directors

Audit Committee

Institutional Investors

Sell-side Analysts

2026 - Chairman of the Board

2022 - Chief Executive Officer

2018 - Chief Financial Officer

2012 - Strategy Committee Member